School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China.
Tianjin Tiancheng Chemical Co., Ltd, Tianjin, China.
Chem Biol Drug Des. 2021 May;97(5):1109-1116. doi: 10.1111/cbdd.13832. Epub 2021 Mar 11.
A series of benz-fused five-membered heterocyclic compounds were designed and synthesized as novel tubulin inhibitors targeting the colchicine binding site. Among them, compound 4d displayed the highest antiproliferative activity against four cancer cell lines with an IC value of 4.9 μM in B16-F10 cells. Compound 4d effectively inhibited tubulin polymerization in vitro (IC of 13.1 μM). Further, 4d induced cell cycle arrest in G2/M phase. Finally, 4d inhibited the migration of cancer cells in a dose-dependent manner. In summary, these results suggest that compound 4d represents a new class of tubulin inhibitors deserving further investigation.
设计并合成了一系列苯并稠合的五元杂环化合物,作为新型微管蛋白抑制剂,以靶向秋水仙素结合位点。其中,化合物 4d 对四种癌细胞系表现出最高的增殖抑制活性,在 B16-F10 细胞中的 IC 值为 4.9 μM。化合物 4d 有效抑制微管蛋白聚合(IC 为 13.1 μM)。此外,4d 诱导细胞周期停滞在 G2/M 期。最后,4d 以剂量依赖的方式抑制癌细胞的迁移。总之,这些结果表明,化合物 4d 代表了一类新的微管蛋白抑制剂,值得进一步研究。